Novartis said its anti-inflammatory drug Cosentyx eased the symptoms of a painful, lump-forming skin condition in two late-stage trials, putting the approved treatment on track to further shore up sales growth at the Swiss drugmaker.
Featured Posts
To innovate, biotechs must choose efficiency over expedience - Being expedient focuses on today’s challenges and needs, and often means skipping steps, estimating rather than calculating, and doing things quickly. Sometimes the expedient solution is necessary; however, it inevitably leads to more work down the road. This is the essence of efficiency – not just fast, but without wasted time and effort.
Biogen announced that its mid-stage monoclonal antibody, litifilimab, is showing promise in reducing joint pain related to systemic lupus erythematosus (SLE) lupus.
Moderna is preparing for multiple product launches over the next several years, including RSV and flu vaccines and boosters for COVID-19. It is also aiming mRNA programs at rare diseases.
Sanofi and Regeneron Pharmaceuticals presented results Friday from the Phase III PRIME trial that showed Dupixent (dupilumab) strongly improves itching and skin lesions in adult patients with prurigo nodularis.
The U.S. Food and Drug Administration has received several reports of certain types of cancers in the scar tissue that forms around breast implants, the agency said in a safety notice on Thursday.
Thousands of FDA employees may lose their jobs if Congress doesn’t reappropriate funding currently in place by the end of the month, according to a report by Bloomberg Law.
The National Institutes of Health said on Thursday it had started enrollments in a trial testing an alternative method of administering Bavarian Nordic’s monkeypox vaccine, Jynneos, which requires smaller dosages.
Bayer said on Thursday its anti-blindness treatment Eylea, jointly developed with Regeneron (REGN.O), has been shown to work as well when given at a higher dose at a longer interval between injections.
Encouraging new data on a malaria vaccine from Oxford University bodes well for global effort to combat the mosquito-borne disease that kills a child every minute, its makers said on Wednesday.
There is no authoritative data on the frequency of suicides among sufferers. Several scientists from organizations including the U.S. National Institutes of Health and Britain’s data-collection agency are beginning to study a potential link following evidence of increased cases of depression and suicidal thoughts among people with long COVID, as well as a growing number of known deaths.